Gold prices steady ahead of Fed decision; weekly weakness noted
In compliance with the UK Financial Conduct Authority’s Disclosure and Transparency Rule 5.6.1, AstraZeneca PLC (LSE:LON:AZN) has announced its total number of voting rights as of March 31, 2025. The biopharmaceutical company, currently valued at $227.57 billion by market capitalization, confirmed that its issued share capital consisted of 1,550,623,487 ordinary shares, each valued at US$0.25, with no shares held in Treasury. Consequently, the total voting rights in the company stand at 1,550,623,487.
This figure serves as a reference for shareholders to determine whether they must notify their interest or any changes to their interest in the company, as per regulatory requirements.
AstraZeneca (NASDAQ:AZN), headquartered in Cambridge, UK, is at the forefront of developing prescription medications across various therapeutic areas, including Oncology, Rare Diseases, and BioPharmaceuticals. The company’s products are available in over 125 countries and continue to impact the lives of patients globally.
The disclosure is based on a press release statement and is intended to keep investors informed of the current voting rights, which could influence shareholder decisions and potential company governance outcomes. For deeper insights into AstraZeneca’s valuation and financial metrics, access the comprehensive Pro Research Report available on InvestingPro, covering over 1,400 top stocks with expert analysis and actionable intelligence.
In other recent news, AstraZeneca has announced several significant developments. The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s drug Imfinzi for the treatment of muscle-invasive bladder cancer (MIBC). This approval is based on the NIAGARA Phase III trial results, which highlighted a 32% reduction in disease progression risk and a 25% reduction in death risk when combined with chemotherapy, followed by Imfinzi as a standalone treatment. Additionally, AstraZeneca’s experimental cholesterol drug AZD0780 demonstrated promising results in a Phase IIb clinical trial, achieving a 50.7% reduction in LDL-C levels over 12 weeks.
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended AstraZeneca’s Calquence for approval as a first-line treatment for mantle cell lymphoma (MCL) in the EU. The recommendation follows the ECHO Phase III trial, which showed a 27% reduction in disease progression risk when Calquence was combined with bendamustine and rituximab. These developments reflect AstraZeneca’s ongoing efforts to expand its portfolio in oncology and cardiovascular treatments. The company continues to make strides in providing new therapeutic options for patients with serious health conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.